First and foremost, if the response from Ed Marshall about Canadian struggles had to be extracted by you as a shareholder, via an email as you say, shame on the company for not updating it's investors about progress or lack thereof.
Secondly, I think I had to read and re-read the post about Mr. Esposito. I guess my first assumption, when I read the initial press release was that Esposito would be an active employee, engaging his full attention to fostering MZEI. When I re-read it, if he is merely a "board member", what in the world is that going to accomplish? Who is actually the "boots on the ground", trying to sell this product? Most BOD I know, also sit on the BOD for various other companies simultaneously, which translates into "Esposito is not dedicating 100 percent of his time to MZEI. He is simply there as most BOD to "advise". To make mention below that announcing Esposito is a "commercial turning point", how can electing a BOD member be a commercial move? A commercial move would relate to sales strategy execution, announcement of product acceptance, etc. etc.
Furthermore, if MZEI team thinks Canadian healthcare has struggles right now, and is impeding sales...what in the world should we think is going to happen in the US? There is not one hospital administrator that has there mind on ANYTHING except for the financial impact of obamacare on their bottomline. Even if EPA gave approval tomorrow for aseptic sure, do you think these hospital administrators would start immediately cutting purchase orders for units? I think not. Hospital administrators focus for the entire next 12 months or more will be on the affects of legislation and potential impact to their bottomline. Period. What does that mean for MZEI? It means more time to pass by, more bleeding cash that they don't have, and another round of "we need more money". Which brings up a whole other subject, where is our funding derived from? Do we still have access to the $10mm line which we have not heard a peep about for years?
Our only inkling of light, would be for someone to buy the intellectual property. Any high powered company with acquisition savvy, would look at our SEC filings and know they could make a lowball offer to obtain the patent. Companies that command good buyout prices, command EBITDA multiples. We don't even have an EBIDTA.